Related Experiment Video
Updated: Jun 19, 2026
13:08
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
Thrombophilia and hypercoagulability
1Department of Medicine, Michigan State University, East Lansing, MI 48824-1313, USA. hassouna@msu.edu
Summary
Thrombophilia and hypercoagulability are distinct conditions impacting thrombosis risk. Understanding their differences is crucial for managing inherited or acquired clotting disorders and preventing recurrent thrombosis.
Area of Science:
- Hematology
- Vascular Biology
- Clinical Medicine
Background:
- Thrombosis involves abnormal fibrin clots causing arterial/venous obstructions.
- Thrombophilia and hypercoagulability are often confused but are distinct entities.
- Thrombophilia is a clinical phenotype with increased thrombosis risk; hypercoagulability is a laboratory phenotype indicating clotting activation.
Purpose of the Study:
- To clarify the less-known aspects of thrombophilia and hypercoagulability in relation to thrombosis.
- To differentiate between thrombophilia and hypercoagulability.
- To review the clinical implications of inherited and acquired thrombophilia.
Main Methods:
- Review of scientific literature and case studies.
- Analysis of data from large family studies on thrombophilia.
- Examination of diagnostic techniques for clotting activation biomarkers.
Main Results:
- Thrombophilia presents as an inherited or acquired clinical phenotype with elevated thrombosis risk.
- Hypercoagulability is a laboratory phenotype reflecting in vivo clotting activation.
- Factors like sepsis, inflammation, and atherosclerosis can provoke hypercoagulability, which may manifest in thrombophilia.
Conclusions:
- Distinguishing thrombophilia from hypercoagulability is essential for accurate diagnosis and management.
- The necessity of treatment after a first thrombotic event in patients with inherited deficiencies requires careful consideration.
- Case vignettes highlight the relationship and distinctions between thrombosis, thrombophilia, and hypercoagulability.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:24Disorders of Hemostasis
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
01:30Venous Thrombosis I: Introduction
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:20Extrinsic and Intrinsic Pathways of Hemostasis
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
01:19Pulmonary Embolism I: Introduction
A blood clot, or thrombus, is a semi-solid mass composed of fibrin, platelets, and red blood cells. When it forms within a vessel, it can obstruct blood flow, known as thrombosis. If part of the clot detaches, it becomes an embolus that can travel and block distant vessels. When this occurs in the pulmonary arteries, it causes a condition known as pulmonary embolism (PE).Origin and ImpactMost often, the embolus originates from a thrombus in the deep veins of the lower limbs, a condition called...